A Loss-of-Function Splice Acceptor Variant in IGF2 Is Protective for Type 2 Diabetes

Broad Genomics Platform, T2D-GENES Consortium, SIGMA T2D Genetics Consortium, Diabetes Prevention Program Research Group

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Type 2 diabetes (T2D) affects more than 415 million people worldwide, and its costs to the health care system continue to rise. To identify common or rare genetic variation with potential therapeutic implications for T2D, we analyzed and replicated genome-wide protein coding variation in a total of 8,227 individuals with T2D and 12,966 individuals without T2D of Latino descent. We identified a novel genetic variant in the IGF2 gene associated with ∼20% reduced risk for T2D. This variant, which has an allele frequency of 17% in the Mexican population but is rare in Europe, prevents splicing between IGF2 exons 1 and 2. We show in vitro and in human liver and adipose tissue that the variant is associated with a specific, allele-dosage-dependent reduction in the expression of IGF2 isoform 2. In individuals who do not carry the protective allele, expression of IGF2 isoform 2 in adipose is positively correlated with both incidence of T2D and increased plasma glycated hemoglobin in individuals without T2D, providing support that the protective effects are mediated by reductions in IGF2 isoform 2. Broad phenotypic examination of carriers of the protective variant revealed no association with other disease states or impaired reproductive health. These findings suggest that reducing IGF2 isoform 2 expression in relevant tissues has potential as a new therapeutic strategy for T2D, even beyond the Latin American population, with no major adverse effects on health or reproduction.

Original languageEnglish (US)
Pages (from-to)2903-2914
Number of pages12
JournalDiabetes
Volume66
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Type 2 Diabetes Mellitus
Protein Isoforms
Alleles
Reproductive Health
Glycosylated Hemoglobin A
Hispanic Americans
Gene Frequency
Population
Reproduction
Adipose Tissue
Exons
Genome
Delivery of Health Care
Costs and Cost Analysis
Liver
Incidence
Health
Therapeutics
Genes
Proteins

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Broad Genomics Platform, T2D-GENES Consortium, SIGMA T2D Genetics Consortium, & Diabetes Prevention Program Research Group (2017). A Loss-of-Function Splice Acceptor Variant in IGF2 Is Protective for Type 2 Diabetes. Diabetes, 66(11), 2903-2914. https://doi.org/10.2337/db17-0187

A Loss-of-Function Splice Acceptor Variant in IGF2 Is Protective for Type 2 Diabetes. / Broad Genomics Platform; T2D-GENES Consortium; SIGMA T2D Genetics Consortium; Diabetes Prevention Program Research Group.

In: Diabetes, Vol. 66, No. 11, 01.11.2017, p. 2903-2914.

Research output: Contribution to journalArticle

Broad Genomics Platform, T2D-GENES Consortium, SIGMA T2D Genetics Consortium & Diabetes Prevention Program Research Group 2017, 'A Loss-of-Function Splice Acceptor Variant in IGF2 Is Protective for Type 2 Diabetes', Diabetes, vol. 66, no. 11, pp. 2903-2914. https://doi.org/10.2337/db17-0187
Broad Genomics Platform, T2D-GENES Consortium, SIGMA T2D Genetics Consortium, Diabetes Prevention Program Research Group. A Loss-of-Function Splice Acceptor Variant in IGF2 Is Protective for Type 2 Diabetes. Diabetes. 2017 Nov 1;66(11):2903-2914. https://doi.org/10.2337/db17-0187
Broad Genomics Platform ; T2D-GENES Consortium ; SIGMA T2D Genetics Consortium ; Diabetes Prevention Program Research Group. / A Loss-of-Function Splice Acceptor Variant in IGF2 Is Protective for Type 2 Diabetes. In: Diabetes. 2017 ; Vol. 66, No. 11. pp. 2903-2914.
@article{eede2fce68774e7b9498ebf886f1b445,
title = "A Loss-of-Function Splice Acceptor Variant in IGF2 Is Protective for Type 2 Diabetes",
abstract = "Type 2 diabetes (T2D) affects more than 415 million people worldwide, and its costs to the health care system continue to rise. To identify common or rare genetic variation with potential therapeutic implications for T2D, we analyzed and replicated genome-wide protein coding variation in a total of 8,227 individuals with T2D and 12,966 individuals without T2D of Latino descent. We identified a novel genetic variant in the IGF2 gene associated with ∼20{\%} reduced risk for T2D. This variant, which has an allele frequency of 17{\%} in the Mexican population but is rare in Europe, prevents splicing between IGF2 exons 1 and 2. We show in vitro and in human liver and adipose tissue that the variant is associated with a specific, allele-dosage-dependent reduction in the expression of IGF2 isoform 2. In individuals who do not carry the protective allele, expression of IGF2 isoform 2 in adipose is positively correlated with both incidence of T2D and increased plasma glycated hemoglobin in individuals without T2D, providing support that the protective effects are mediated by reductions in IGF2 isoform 2. Broad phenotypic examination of carriers of the protective variant revealed no association with other disease states or impaired reproductive health. These findings suggest that reducing IGF2 isoform 2 expression in relevant tissues has potential as a new therapeutic strategy for T2D, even beyond the Latin American population, with no major adverse effects on health or reproduction.",
author = "{Broad Genomics Platform} and {T2D-GENES Consortium} and {SIGMA T2D Genetics Consortium} and {Diabetes Prevention Program Research Group} and Mercader, {Josep M.} and Liao, {Rachel G.} and Bell, {Avery D.} and Zachary Dymek and Karol Estrada and Taru Tukiainen and Alicia Huerta-Chagoya and Hortensia Moreno-Mac{\'i}as and Jablonski, {Kathleen A.} and Hanson, {Robert L.} and Walford, {Geoffrey A.} and Ignasi Moran and Ling Chen and Vineeta Agarwala and Ordo{\~n}ez-S{\'a}nchez, {Mar{\'i}a Luisa} and Rosario Rodr{\'i}guez-Guillen and Maribel Rodr{\'i}guez-Torres and Yayoi Segura-Kato and Humberto Garc{\'i}a-Ortiz and Federico Centeno-Cruz and Francisco Barajas-Olmos and Lizz Caulkins and Sobha Puppala and Pierre Fontanillas and Williams, {Amy L.} and S{\'i}lvia Bon{\`a}s-Guarch and Chris Hartl and Stephan Ripke and Katherine Tooley and Jacqueline Lane and Carlos Zerrweck and Ang{\'e}lica Mart{\'i}nez-Hern{\'a}ndez and C{\'o}rdova, {Emilio J.} and Elvia Mendoza-Caamal and Cecilia Contreras-Cubas and Gonz{\'a}lez-Villalpando, {Mar{\'i}a E.} and Ivette Cruz-Bautista and Liliana Mu{\~n}oz-Hern{\'a}ndez and Donaji G{\'o}mez-Velasco and Ulises Alvirde and Henderson, {Brian E.} and Wilkens, {Lynne R.} and {Le Marchand}, Loic and Sergio Islas-Andrade and Lehman, {Donna M.} and Hanis, {Craig L.} and Stacey Gabriel and Abboud, {Hanna E.} and Daniel MacArthur and Jorge Ferrer",
year = "2017",
month = "11",
day = "1",
doi = "10.2337/db17-0187",
language = "English (US)",
volume = "66",
pages = "2903--2914",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - A Loss-of-Function Splice Acceptor Variant in IGF2 Is Protective for Type 2 Diabetes

AU - Broad Genomics Platform

AU - T2D-GENES Consortium

AU - SIGMA T2D Genetics Consortium

AU - Diabetes Prevention Program Research Group

AU - Mercader, Josep M.

AU - Liao, Rachel G.

AU - Bell, Avery D.

AU - Dymek, Zachary

AU - Estrada, Karol

AU - Tukiainen, Taru

AU - Huerta-Chagoya, Alicia

AU - Moreno-Macías, Hortensia

AU - Jablonski, Kathleen A.

AU - Hanson, Robert L.

AU - Walford, Geoffrey A.

AU - Moran, Ignasi

AU - Chen, Ling

AU - Agarwala, Vineeta

AU - Ordoñez-Sánchez, María Luisa

AU - Rodríguez-Guillen, Rosario

AU - Rodríguez-Torres, Maribel

AU - Segura-Kato, Yayoi

AU - García-Ortiz, Humberto

AU - Centeno-Cruz, Federico

AU - Barajas-Olmos, Francisco

AU - Caulkins, Lizz

AU - Puppala, Sobha

AU - Fontanillas, Pierre

AU - Williams, Amy L.

AU - Bonàs-Guarch, Sílvia

AU - Hartl, Chris

AU - Ripke, Stephan

AU - Tooley, Katherine

AU - Lane, Jacqueline

AU - Zerrweck, Carlos

AU - Martínez-Hernández, Angélica

AU - Córdova, Emilio J.

AU - Mendoza-Caamal, Elvia

AU - Contreras-Cubas, Cecilia

AU - González-Villalpando, María E.

AU - Cruz-Bautista, Ivette

AU - Muñoz-Hernández, Liliana

AU - Gómez-Velasco, Donaji

AU - Alvirde, Ulises

AU - Henderson, Brian E.

AU - Wilkens, Lynne R.

AU - Le Marchand, Loic

AU - Islas-Andrade, Sergio

AU - Lehman, Donna M.

AU - Hanis, Craig L.

AU - Gabriel, Stacey

AU - Abboud, Hanna E.

AU - MacArthur, Daniel

AU - Ferrer, Jorge

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Type 2 diabetes (T2D) affects more than 415 million people worldwide, and its costs to the health care system continue to rise. To identify common or rare genetic variation with potential therapeutic implications for T2D, we analyzed and replicated genome-wide protein coding variation in a total of 8,227 individuals with T2D and 12,966 individuals without T2D of Latino descent. We identified a novel genetic variant in the IGF2 gene associated with ∼20% reduced risk for T2D. This variant, which has an allele frequency of 17% in the Mexican population but is rare in Europe, prevents splicing between IGF2 exons 1 and 2. We show in vitro and in human liver and adipose tissue that the variant is associated with a specific, allele-dosage-dependent reduction in the expression of IGF2 isoform 2. In individuals who do not carry the protective allele, expression of IGF2 isoform 2 in adipose is positively correlated with both incidence of T2D and increased plasma glycated hemoglobin in individuals without T2D, providing support that the protective effects are mediated by reductions in IGF2 isoform 2. Broad phenotypic examination of carriers of the protective variant revealed no association with other disease states or impaired reproductive health. These findings suggest that reducing IGF2 isoform 2 expression in relevant tissues has potential as a new therapeutic strategy for T2D, even beyond the Latin American population, with no major adverse effects on health or reproduction.

AB - Type 2 diabetes (T2D) affects more than 415 million people worldwide, and its costs to the health care system continue to rise. To identify common or rare genetic variation with potential therapeutic implications for T2D, we analyzed and replicated genome-wide protein coding variation in a total of 8,227 individuals with T2D and 12,966 individuals without T2D of Latino descent. We identified a novel genetic variant in the IGF2 gene associated with ∼20% reduced risk for T2D. This variant, which has an allele frequency of 17% in the Mexican population but is rare in Europe, prevents splicing between IGF2 exons 1 and 2. We show in vitro and in human liver and adipose tissue that the variant is associated with a specific, allele-dosage-dependent reduction in the expression of IGF2 isoform 2. In individuals who do not carry the protective allele, expression of IGF2 isoform 2 in adipose is positively correlated with both incidence of T2D and increased plasma glycated hemoglobin in individuals without T2D, providing support that the protective effects are mediated by reductions in IGF2 isoform 2. Broad phenotypic examination of carriers of the protective variant revealed no association with other disease states or impaired reproductive health. These findings suggest that reducing IGF2 isoform 2 expression in relevant tissues has potential as a new therapeutic strategy for T2D, even beyond the Latin American population, with no major adverse effects on health or reproduction.

UR - http://www.scopus.com/inward/record.url?scp=85037582424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037582424&partnerID=8YFLogxK

U2 - 10.2337/db17-0187

DO - 10.2337/db17-0187

M3 - Article

VL - 66

SP - 2903

EP - 2914

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 11

ER -